Bulent Yalcin - Ankara Yildirim Beyazit University

基本信息

浏览量：35

职业迁徙

个人简介

Bulent Yalcin currently works at the Faculty of Medicine, Dept.of Med. Oncology, Ankara Yildirim Beyazit University. Bulent does research in Clinical Trials,

研究兴趣

论文共 225 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Do Metastatic Volumes Measured in Breast Cancer Patients with Bone Metastases Correlate with the Numbers of Skeletal and Extraskeletal Events

Hilal Yagar,Mahmut Nedim Aytekin,Didem Sener Dede,Mehmet Ali Nahit Sendur,Recep Ozturk,Buelent Yalcin

JOINT DISEASES AND RELATED SURGERYno. 1 (2024): 105-111

引用0浏览0WOS引用

A Current Comprehensive Role of Immune-Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer: A Narrative Review

Safa Can Efil,Burak Bilgin,Furkan Ceylan,Hilal Karakas,Irfan Karahan, Sema Nur Ozsan,Hakan Kosku,Sebnem Yaman,Muhammed Bulent Akinci,Didem Sener Dede,Buelent Yalcin,Mehmet Ali Nahit Sendur

Journal of oncology pharmacy practice official publication of the International Society of Oncology Pharmacy Practitionersno. 7 (2024): 1214-1239

引用0浏览0WOS引用

Effect of HER2/CEP17 Ratio on Survival in Metastatic HER2-positive Gastric Cancer, Multicenter Study

Serhat Sekmek,Irfan Karahan,Gokhan Ucar,Furkan Ceylan,Dogan Bayram,Ismet Seven,Hatice Bölek,Yüksel Ürün,Kadriye Bir Yücel,Ozan Yazici,Ahmet Kadioglu,Cengiz Karacin,Kubra Canaslan,Elif Atag,Serhat Demirer,Gokmen Umut Erdem,Yakup Ergun, Mehmetcan Atak, Baris Koksal,Merve Meryem Kiran, Duriye Ozer Turkay,Burak Civelek,Bulent Yalcin,Dogan Uncu

CLINICAL & TRANSLATIONAL ONCOLOGYno. 8 (2024): 1878-1885

引用0浏览0WOS引用

Comparison of Anthracycline-Containing and Anthracycline-Free Regimens in Neoadjuvant HER-2 Positive Breast Cancer Treatment

Murat Bardakci,Hilal Karakas,Dogan Bayram,Nilufer Avci, Sait Kitapli,Mirac Ozen,Ferit Aslan, Caglar Koseoglu,Ahmet Kadioglu, Ilknur D. Onur,Teoman Sakalar,Mahmut Buyuksimsek,Ali Alkan,Yakup Ergun, Ali O. Kaya,Burak Bilgin,Bulent Yalcin

SCIENTIFIC REPORTSno. 1 (2024)

引用0浏览0WOSNATURE引用

Are the Clinical Trials in Lung Cancer an Advantage for Patients in Developing Countries

Cihan Erol,Mutlu Hizal,Seda Kahraman,Murat Bardakci, Didem Sener Dede,Muhammed Bulent Akinci,Bulent Yalcin, Mehmet Ali Nahit Sendur

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Clinical Presentation and Prognostic Factors of Primary Appendix Malignancies: A Retrospective Evaluation

Murat BARDAKÇI,Derya DEMİRTAŞ ESMER,Emre Hafızoğlu,Hilal KARAKAŞ,Öznur Bal,Efnan Algın,Muhammed Bülent Akıncı,Bülent YALÇIN

Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi dergisino. 2 (2023): 296-304

引用0浏览0引用

Inci Elif Erbahceci Timur,Vehbi Acikgoz,Nagihan Ugurlu,Buelent Yalcin,Mehmet Ali Nahit Sendur,Mutlu Hizal,Halil Kara

CUTANEOUS AND OCULAR TOXICOLOGYno. 3 (2023): 109-117

引用0浏览0WOS引用

Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Cihan EROL,Murat BARDAKÇI,Mutlu HIZAL,Seda KAHRAMAN,Emre Yekedüz,Deniz Can Güven,Musa Barış AYKAN,Recep Ak,Öztürk ATEŞ,Didem Şener Dede,Muhammed Bülent Akıncı,Nuri KARADURMUŞ,Öznur Bal,Yüksel ÜRÜN,Şuayib Yalçın,Bülent YALÇIN,Mehmet Ali Nahit ŞENDUR

Journal of oncological scienceno. 2 (2023): 72-78

引用0浏览0引用

Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

Cihan Erol,Emre Hafızoğlu,Musa Barış Aykan,Deniz Can Güven,Bengü Dursun,Mutlu Hızal,Seda Kahraman,Didem Şener Dede,Muhammed Bülent Akıncı,Nuri Karadurmuş,Yüksel Ürün,Efnan Algın,Şuayib Yalçın,Bülent Yalçın,Mehmet Ali Nahit Şendur

Acta Oncologica Turcicano. 2 (2023): 170-179

引用0浏览0引用

The Diurnal Change of Thyroid-Stimulating Hormone and the Effect of This Change on Thyroid Functions in Patients with Chronic Kidney Disease

Hüseyin Soylu,Reyhan Ersoy, Pelin Bal Keske,Merve Ergin Tunçay, Can Ateş,Bekir Çakır,Bülent Yalçın

Endocrine（2023）

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn